Login Preferences
About News Publications Statistics Downloads API Guide License How to use Preferences
bn:01179777n
Noun Concept
Categories: All articles lacking reliable references, Drugboxes which contain changes to watched fields, Alcohols, Triazolopyrimidines, AstraZeneca brands
EN
ticagrelor  (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol  AR-C126532XX  ATC code B01AC24  ATCvet code QB01AC24
EN
Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. Wikipedia
Definitions
Relations
Sources
EN
Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. Wikipedia
Coronary medication Wikidata
IS A
compound
medicine
MEDICAL CONDITION TREATED
acute coronary syndrome
unstable angina
heart disease
Wikipedia
EN
ticagrelor
Wikidata
EN
ticagrelor
Wikipedia Redirections
EN
ATC code B01AC24, ATCvet code QB01AC24, AZD6140, Brilinta, Brilique, C23H28F2N6O4S, Possia, ticagrelol, Tigralor, Tigrelor
Wikidata Alias
EN
AR-C126532XX, AZD-6140, AZD6140, AZD 6140, Brilinta®, Brilique®, Ticagrelor, (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, (1S,2S,3R,5S)-3-(7-((1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino)-5-(propylthio)-3H-(1,2,3)triazolo(4,5-D)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol

Please note that, in order to improve your browsing experience on this website, BabelNet® uses various types of cookies, including: browsing functionality, performance and statistical cookies.

By continuing to browse the site you are agreeing to our use of cookies. OK

License